December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Telix Pharmaceuticals Limited - American Depositary Shares (NQ:TLX)

10.86 +0.35 (+3.33%)
Streaming Delayed Price Updated: 10:14 AM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Telix Pharmaceuticals Limited - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FDA Alignment to Advance ProstACT Global Phase 3 Trial
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and United Imaging Announce Strategic Theranostics Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
IPAX-2 Study of TLX101-Tx in First-line Glioblastoma Completes Enrolment and Confirms Dosing
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Announces Collaborations to Explore PSMA-PET Imaging in Emerging Prostate Cancer Treatment Approaches
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
TLX101-Px (Pixlumi®) MAA Accepted in Europe
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Educational Webinar: Unlocking the Potential of PSMA Therapy, A Next‑Generation Portfolio Approach
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 (Part 1) Selected as Late-Breaking Abstract at ASCO 2026
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Doses First Patient in Phase 3 IPAX-BrIGHT Trial of TLX101-Tx for Recurrent Glioblastoma
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix and Regeneron Announce Strategic Radiopharma Collaboration
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Regeneron and Telix Announce Strategic Radiopharma Collaboration
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
FDA Accepts NDA for TLX101-Px (Pixclara®)
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Strengthens Board with Additional Director Appointments
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Q1 2026: Strong Revenue Growth and Therapeutics Pipeline Advancement
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Appoints David Gill as Non-Executive Director
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Resubmits NDA to U.S. FDA for TLX101-Px (Pixclara®) Brain Cancer Imaging Candidate
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
ProstACT Global Phase 3 Study (Part 1) Achieves Primary Objectives
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Investor Education Webinar
The Future of Prostate Imaging: What do physicians want? 
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Joins Forces with University Hospital Essen on PROMISE-PET: Optimizing Patient Management through AI-enabled PSMA-PET Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix to Participate in Oppenheimer and TD Cowen Conferences
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
FY 2025 Results: Strong Commercial Growth, Focused Pipeline Investment
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging
From Telix Pharmaceuticals Limited
Via GlobeNewswire
News headline image
Telix Full Year Results 2025 Investor Webcast Notification
From Telix Pharmaceuticals Limited
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.